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Abstract
Background: Microbial translocation may contribute to the immunopathogenesis in HIV infection. We investigated if
microbial translocation and inflammation were associated with innate and adaptive immune responses in adults with
HIV.
Methodology/Principal Findings: This was an observational cohort study. Sera from HIV-infected and HIV-uninfected
individuals were analyzed for microbial translocation (soluble CD14, lipopolysaccharides [LPS], endotoxin core antibody, and
anti-a-galactosyl antibodies) and inflammatory markers (high sensitivity C-reactive protein, IL-6, IL-1 receptor antagonist,
soluble tumor necrosis factor receptor II, and IL-10) with enzyme-linked immunosorbent assays. Peripheral blood
mononuclear cells (PBMC) from HIV-infected persons and healthy controls (primed with single-stranded HIV-1-derived RNA)
were stimulated with LPS, and cytokine production was measured. Finally, HIV-infected patients were immunized with
Prevnar 7vPnC6CpG 7909 followed by Pneumo Novum PPV-23. Effects of microbial translocation and inflammation on
immunization were analyzed in a predictive regression model. We included 96 HIV-infected individuals, 76 on highly active
antiretroviral therapy (HAART), 20 HAART-naive, and 50 healthy controls. Microbial translocation and inflammatory markers
were higher among HIV-infected persons than controls. Cytokine levels following LPS stimulation were increased in PBMCs
from HAART-naive compared to HAART-treated HIV-infected persons. Further, RNA-priming of PBMCs from controls acted
synergistically with LPS to augment cytokine responses. Finally, high serum LPS levels predicted poor vaccine responses
among HAART-naive, but not among HAART-treated HIV-infected individuals.
Conclusions/Significance: LPS acts synergistically with HIV RNA to stimulate innate immune responses in vitro and
increasing serum LPS levels seem to predict poor antibody responses after vaccination among HAART-naive HIV-infected
persons. Thus, our results suggest that microbial translocation may be associated with innate and adaptive immune
dysfunction in untreated HIV infection.
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Introduction
Untreated HIV infection is characterized by progressive
immune dysfunction. In the first weeks of infection, immense
CD4+ T cell depletion and active viral replication occur,
particularly in the intestinal mucosa [1,2,3]. This, in turn, leads
to elevated levels of pro-inflammatory cytokines, increased
apoptosis of epithelial cells, and altered tight junction protein
composition [4] resulting in a functional degradation of the
intestinal barrier [5]. These events are thought to induce microbial
translocation, an enhanced transit of microbial products through
intestinal mucosa to the blood stream.
Lipopolysaccharides (LPS) and LPS-related markers such as
soluble CD14 (sCD14) have been used to quantify microbial
translocation in peripheral blood [3,6]. Anti-a-galactosyl (anti-Gal)
immunoglobulins are potential novel markers that have not yet
been tested in HIV patients [7]. Anti-Gal IgM and IgG interact
specifically with the unique Gala1-3Galb1-4GlcNAc-R epitope (a-
galactosyl epitope) [8], which is found on the surface of cells of
various organisms from prokaryotes to non-primate mammals
[8,9,10]. Microbial translocation has also been observed in other
clinical conditions including depression, burn injury, sepsis
secondary to bacterial pneumonia, acute pancreatitis, and in
excessive alcohol consumption [11,12,13,14,15]. Recently, North
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and sCD14 plasma levels, as well as immune activation, were
increased among highly active antiretroviral therapy (HAART)-
naive HIV-infected persons compared to HAART-treated HIV-
infected and HIV-uninfected individuals [3,16,17,18,19], while in
a Kenyan cohort both untreated and treated chronic HIV-infected
subjects had significantly elevated levels of LPS [20]. Thus,
microbial translocation may contribute to the persistent immune
activation in HIV infection [3,16,17] and levels of LPS have been
shown to correlate with disease severity in both HIV-1 and HIV-2
infections [21]. This hypothesis has been contradicted by findings
from a longitudinal study of HIV-seroconverters in Uganda, which
found no association between microbial translocation and HIV
disease progression over an eight-year period [22]. Hence, the
impact of microbial translocation on the immune system of people
with HIV remains uncertain. Therefore, the objective of this study
was to investigate if microbial translocation and inflammation
were associated with innate and adaptive immune responses in
adults with and without HIV.
Methods
Study design
This was an observational cohort study. Patients were recruited
from a vaccination cohort consisting of otherwise healthy HIV-
infected adults immunized with pneumococcal vaccines with or
without CPG 7909 [23] (Text S1). HIV-uninfected controls were
recruited from the blood bank at Aarhus University Hospital,
Skejby, Denmark. Serum samples were stored at 280uC, while
peripheral blood mononuclear cells (PBMCs) were stored at
2170uC. The study was conducted at the Department of
Infectious Diseases at Aarhus University Hospital, Skejby, Den-
mark. Written informed consent was obtained for all participants.
Study protocols (Text S2) were approved by the Research Ethics
Committee, Danish Data Protection Agency, and Danish
Medicines Agency and registered at www.clinicaltrials.gov
(NCT00562939). The methods and results from the main trial
have been described elsewhere in details [23].
Soluble markers of microbial translocation and pro-
inflammation
Microbial translocation was investigated by quantification of
sCD14, LPS, endotoxin core antibody IgG (endoCAb) (Hycult
biotech), and anti-a-galactosyl antibodies (anti-Gal IgM and IgG)
in serum samples. Inflammation was quantified by measuring
serum levels of soluble tumor necrosis factor receptor II (sTNF-
rII), interleukin-1 receptor antagonist (IL-1Ra), high sensitivity C-
reactive protein (hs-CRP), interleukin-6 (IL-6), and interleukin-10
(IL-10) by enzyme-linked immunosorbent assay (ELISA) (RnD
Systems and Invitrogen, DK). LPS levels were evaluated with a
chromogenic limulus amebocyte lysate assay (LAL assay, QCL-
1000
H, Lonza, DK). The anti-Gal antibody assay was an in-house
time-resolved immunofluorometric assay (TRIFMA). Briefly,
plates were coated with 100 mL/well a-galactosyl-human serum
albumin (a-Gal-HSA) glycoconjugates (Dextra, UK) or HSA
(0.25 mg/mL), incubated in a humidifier over night at 4uC, and
then blocked one hour with 1 mg HSA/mL tris-buffered saline
(TBS). Next, 100 mL/well diluted serum samples, controls, blanks,
and standard curve samples were added in duplicate. Following an
over night incubation, biotinylated anti-human-IgG or –anti-
human-IgM antibodies were added (100 mL/well, 0.2 mg/mL).
After one hour, streptavidin-Eu was added to the plate. After an
additional hour, Enhancement solution (PerkinElmer) was added.
Counts per second were measured for each well on a Victor 3
Multilabel Reader (PerkinElmer). The relevant anti-HSA signal
was subtracted from anti-a-Gal-HSA signals. Corrected signals
were converted to measures of antibody concentration by relating
them to a standard curve (the antibody concentration of standard
curve samples with dilutions similar to samples were assigned a
value of 100 AU). All other assays were performed according to
the manufacturer’s protocol. Up to three freeze-thaw cycles were
performed on serum samples. Median intra-assay and inter-assay
coefficients of variation for all markers were below 15%. All serum
measurements were performed on pre-vaccinated samples.
Responsiveness to LPS stimulation
The impact of HIV RNA and LPS on pro-inflammatory
cytokine secretion was investigated in PBMCs from 20 HAART-
treated and 20 HAART-naive individuals with HIV (with
matched CD4+ cell count, age, and sex) with PBMCs exposed
to one freeze-thaw cycle. For 48 hours, the PBMCs were either
stimulated with 100 ng/mL LPS (Invivogen, France) or left
untreated. A 25-plex cytokine luminex assay (Invitrogen, DK)
was used to measure a large range of cytokines in harvested cell
culture supernatants for instance TNF-a, IFN-a, and IFN-c.
The co-stimulatory effect of viral RNA on LPS-induced
cytokine production was further investigated in PBMCs from
HIV-uninfected controls, which were exposed to one freeze-thaw
cycle. PBMCs were either primed by transfection with increasing
concentrations of HIV-1-derived single-stranded RNA (ssRNA40:
0, 0.01, 0.1, or 1.0 mg/mL) or unrelated control RNA (ssRNA41:
0.1 mg/mL) (both Invivogen, France). After incubation for
24 hours, PBMCs were stimulated with LPS at increasing
concentrations (0, 1, 10, or 100 ng/mL). Supernatants were
harvested and stored at 280uC. The pro-inflammatory marker
TNF-a was measured in cell culture supernatants using a Cytoset
ELISA (Invitrogen, DK).
Adaptive immune response
All HIV-infected subjects were immunized, and all together
three doses of vaccine were given. First with double the standard
dose of 7-valent pneumococcal conjugated vaccine (7vPnC,
PrevnarH, Wyeth) 6adjuvant (1 mg CpG 7909, Pfizer) at 0 and
3 months and with one single dose of 23-valent polysaccharide
vaccine (PPV-23) (Pneumo Novum
H, Sanofi-Pasteur MSD) 61m g
CpG 7909 at 9 months [23]. Participants were also seen at 4 and
10 months for immunogenicity and safety follow-up.
Immune responses to pneumococcal vaccination were quanti-
fied by specific anticapsular IgG levels for all seven 7vPnC vaccine
serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) [24] using a
standardized ELISA by Statens Serum Institut, Denmark [25].
Serum samples were pre-adsorbed with optimal concentrations of
pneumococcal cell wall and 22F capsular polysaccharides [26].
Statistical analysis
HIV-infected individuals were categorized as ‘‘HAART-naive’’
if they had never been exposed to antiretroviral drugs or
‘‘HAART-treated’’ if, at inclusion, they received either a 3-drug
regimen including a non-nucleoside reverse transcriptase inhibitor,
a protease inhibitor, and/or abacavir or a 2-drug combination of a
non-nucleoside reverse transcriptase inhibitor and a boosted
protease inhibitor. All HAART-treated HIV-infected individuals
had been treated for at least six months and had undetectable viral
load at enrollment. HIV-uninfected persons were referred to as
‘‘controls’’.
Medians and interquartile ranges (IQR) were calculated for all
continuous variables. Sensitivity analyses were conducted to
evaluate if participants, who on a single occasion demonstrated
Impact of LPS on Adaptive Immunity
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differences. Kruskal-Wallis rank test was used for comparison of
more than two variables. Student’s t-test was applied to test
differences in the markers between groups. Logarithmic transfor-
mations (log10) were made when continuous outcomes did not
follow a normal distribution. When logarithmic transformed
values did not follow a normal distribution, Mann-Whitney rank
sum was used. Spearman’s correlation was used to evaluate
correlations between markers.
LPS-responsiveness in PBMCs from HIV-infected individuals
was evaluated by a stimulation index as the ratio between secreted
cytokines from LPS-stimulated and untreated PBMCs. The
measure of adaptive immune response was an aggregated outcome
based on measurements of vaccine-specific antibodies (at 0, 3, 4, 9,
and 10 months). To account for missing data, we employed a
multiple imputation strategy [33] utilizing a monotone missing
data pattern (no subjects re-entered the study after being lost to
follow-up). This implied the model for imputations of an outcome
could be based on values of the outcome at previous time points (3
withdrew consent, 4 were lost to follow-up, 1 was inappropriately
enrolled, overall [23]). The effect of vaccination was estimated in a
mixture model where current smoking status (yes/no), age, pre-
vaccination CD4+ cell count, HIV RNA (log10), and TLR9
agonist-adjuvant (yes/no) in the pneumococcal vaccine were
considered the fixed effects, whereas each individual was allowed a
random intercept and random slope with respect to time.
Correlation between the two random effects was allowed. Thus,
individual random effects accounted for the variation between
individuals in level and trend over time. For each marker, an
estimate was calculated with a 95% confidence interval. The
multivariate analysis was used to adjust for the known confound-
ers. For all microbial translocation and inflammatory markers, we
calculated both unadjusted and adjusted estimates (adjusted for
current smoking status (yes/no), age, pre-vaccination CD4+ cell
count, HIV RNA (log10), and TLR9 agonist-adjuvant (yes/no)).
Analyses were stratified according to use of HAART at time of
immunization. A significant estimate indicated the marker in
question was able to predict the outcome of an antibody response.
Stata 11.0 was used for all statistic analyses and the level of
significance was set at 0.05.
Results
The study included 96 HIV-infected individuals (20 HAART-
naive and 76 HAART-treated) and 50 controls. Pre-vaccination
characteristics and laboratory results for all subjects are shown in
Table 1. No significant differences were found between HAART-
treated and HAART-naive subjects in terms of CD4+ cell count,
age, and sex. The median age of controls was lower than for
HAART-treated and HAART-naive subjects.
Microbial translocation in HIV-infected individuals
Soluble CD14 levels were significantly higher in HIV-infected
subjects (6.58 mg/mL, IQR: 4.88–9.47) than in controls
(3.12 mg/mL, IQR: 2.76–3.66, p,0.001), and there was a trend
towards higher LPS in HIV-infected subjects (1.67 EU/mL, IQR:
1.30–2.06) compared to controls (1.43 EU/mL, IQR: 1.14–1.88,
p=0.06) (Fig. 1A and B). HIV-infected participants were stratified
by use or non-use of HAART (Table 1). Between HIV-infected
subjects and controls, no difference in endoCAb level was found
(26.2 GMU/mL, IQR: 15.6–48.8 vs. 34.6 GMU/mL, IQR:
25.4–56.9, p=0.08) (Fig. 1C). No difference was found in anti-
Gal IgM levels between HIV-infected individuals (163 AU, IQR:
89.4–389) and controls (152 AU, IQR: 78.3–564, p=0.57)
Table 1. Characteristics and laboratory results for all participants pre-vaccination.
HAART-treated (n=76) HAART-naive (n=20) Controls (n=50) P
a
Age, years
b 48.9 (42.8–59.9) 48.2 (40.6–55.3) 41.3 (31.3–51.3) ,0.0008
Sex, male, n (%) 65 (85.5) 16 (80) 30 (60) =0.004
BMI index
c 23.5 (21.7–25.2) 24.6 (22.6–26.5) - =0.19
CD4+ cell count, cells/mL 641 (489–837) 497 (373–812) - =0.25
CD4 nadir, cells/mL 201 (71–243) 401 (313–659) - ,0.0001
Log10 HIV RNA 1.60 (1.60–1.60) 4.33 (3.72–4.70) - ,0.0001
Current smokers, n (%) 26 (34.2) 9 (45) - ,0.001
sCD14, mg/mL 6.57 (4.85–9.39) 7.24 (5.07–11.4) 3.12 (2.76–3.66) ,0.0001
LPS, EU/mL 1.62 (1.28–2.07) 1.71 (1.49–1.98) 1.43 (1.14–1.88) =0.16
EndoCAb, GMU/mL 27.3 (15.4–51.7) 24.5 (17.1–36.5) 34.6 (25.4–56.9) =0.04
Anti-Gal
d IgM, AU
e 178 (89.4–386) 140 (78.4–540) 152 (78.3–564) =0.83
Anti-Gal IgG, AU 9.28 (3.81–23.1) 9.30 (6.09–24.2) 13.38 (6.91–27.2) =0.30
sTNF-rII, ng/mL 5.0 (3.6–6.2) 5.8 (4.6–8.4) 4.3 (3.7–4.8) ,0.0002
IL-1Ra, pg/mL 66 (39–104) 88 (70–117) 67 (47–93) =0.044
hs-CRP, mg/mL 5.47 (2.18–13.0) 5.42 (1.79–8.15) 2.49 (1.00–7.52) =0.01
IL-6, pg/mL 0.32 (0.12–0.60) 0.44 (0.28–0.78) 0.13 (0.09–0.37) =0.006
IL-10, pg/mL 1.49 (0.77–2.27) 2.88 (1.79–3.87) 2.07 (1.13–3.86) ,0.001
aGlobal p-value, Kruskal-Wallis rank test.
bUnless otherwise indicated the median (IQR, interquartile range) is given.
cBMI, body mass index.
dAnti-Gal, anti-a-galactosyl.
eAU, arbitrary units.
doi:10.1371/journal.pone.0021275.t001
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jects and controls (9.28 AU, IQR: 4.00–23.1 vs. 13.4 AU, IQR:
6.91–27.2, p=0.14) (Fig. 1E). No associations with HIV RNA,
current or nadir CD4+ cell count were observed for either of
the markers, and concentrations of sCD14, LPS, endoCAb, and
anti-Gal IgM and IgG were comparable between HAART-treated
and HAART-naive subjects. In addition, we found no significant
associations between anti-Gal IgM and anti-Gal IgG with either
sCD14 or LPS. An association was found between anti-Gal IgG
and endoCAb for HIV-infected subjects, both HAART-naive and
subjects on HAART treatment. No other associations were found
between endoCAb and the other microbial translocation markers.
Finally, sensitivity analyses revealed no impact of age on any of the
microbial translocation markers.
Elevated pro-inflammatory cytokine levels in HIV-infected
individuals
The levels of the pro-inflammatory markers, sTNF-rII and IL-6,
were significantly higher in HAART-treated and HAART-naive
individuals compared with controls (Table 1). Compared with
HAART-treated, HAART-naive subjects had higher serum levels
of sTNF-rII (5.8 ng/mL, IQR: 4.6–8.4 vs. 5.0 ng/mL, IQR:
3.6–6.2, p=0.03), IL-1Ra (88 pg/mL, IQR: 70–117 vs. 66
pg/mL, IQR: 39–104, p=0.03), and IL-10 (2.9 pg/mL, IQR:
1.8–3.9 vs. 1.5 pg/mL, IQR: 0.8–2.3, p=0.02). A near-significant
correlation was observed between sCD14 and sTNF-rII in
HIV-infected subjects (p=0.053, rho=0.20), but we found no
associations between sCD14 and the other pro-inflammatory
markers, or between LPS and any of the pro-inflammatory
markers in either of the groups, except IL-10 in HAART-naive
subjects (p,0.01, rho=20.57). IL-10 showed a positive association
with both sTNF-rII and IL-1Ra in HIV-infected subjects
(sTNF-rII: p,0.001, rho=0.35 and IL-1Ra: p,0.01, rho=0.31).
No significant associations were found between CD4+ cell counts
or HIV RNA levels and any of the markers for pro-inflammation,
except for IL-10, where all HIV-infected subjects had a negative
association with CD4+ cell count (p=0.013, rho=20.25) and a
positive correlation with HIV RNA level (p,0.01, rho=0.28).
Sensitivity analyses revealed no impact of age on any of the pro-
inflammation markers, except for IL-10 in HAART-treated
HIV-infected subjects, which showed a negative association
between age and IL-10 (p=0.04, rho=20.24).
Figure 1. Microbial translocation in HIV-infected individuals and HIV-uninfected controls. (A) Median serum level of LPS in our cohort;
controls: 1.55 EU/mL, HIV-infected persons: 1.82 EU/mL, p=0.061. (B) Median serum level of sCD14 in our cohort; controls: 3.18 mg/mL, HIV-infected
persons: 7.58 mg/mL, p,0.001. (C) Median serum level of endoCAb in our cohort; controls: 34.6 GMU/mL, HIV-infected persons: 26.2 GMU/mL,
p=0.08. (D) Median serum level of anti-Gal IgM in our cohort; controls: 288.4 AU, HIV-infected persons: 171.2 AU, p=0.57. (E) Median serum level of
anti-Gal IgG in our cohort; controls: 13.38 AU, HIV-infected persons: 9.28 AU, p=0.14.
doi:10.1371/journal.pone.0021275.g001
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Following LPS stimulation of PBMCs, greater stimulation
indexes were observed in HAART-naive subjects compared with
HAART-treated subjects for the main pro-inflammatory cyto-
kines, TNF-a (p=0.03), IFN-a (p=0.002), and IFN-c (p=0.003)
(Fig. 2A-C). We also observed significantly higher stimulation
indexes for IL-1Ra (p=0.004), IL-2R (p=0.02), IL-5 (p=0.01), IL-8
(p=0.005), IL-13 (p=0.02),and IP-10 (p=0.04) in the HAART-naive
individuals compared with HAART-treated subjects (data not
shown). The HIV RNA and TNF-a stimulation indexes positively
correlated inHAART-naive individuals (Fig. 2D),which suggested a
dose-dependent relationship between HIV RNA and TNF-a
produced by the LPS-stimulated PBMCs.
Responsiveness of single-stranded RNA40-primed PBMCs
to LPS in vitro
In PBMCs from HIV-uninfected controls, we found higher
TNF-a responses in cells primed with HIV-1-derived single-
stranded RNA (ssRNA40) (n=4) compared with un-primed
and unrelated ssRNA41-primed PBMCs after LPS stimulation
(Fig. 2E). Both in non-LPS-stimulated and LPS-stimulated PBMCs
we had significant results between unprimed and primed PBMCs
(0, 1, 10, and 100 ng/mL LPS stimulated PBMCs, all p,0.001).
TNF-a levels increased up to 100-fold after LPS stimulation (from
0 ng/mL LPS to 10 ng/mL LPS), which suggests a synergetic
effect between LPS and HIV RNA. No additional increase in
TNF-a production was observed by increasing LPS exposure from
10 to 100 ng/mL. Similar results were observed with other
concentrations of ssRNA40 (0.01 and 1.0 mg/mL, Figure S1).
High serum LPS levels predict poor adaptive immune
responses in HAART-naive individuals
In HAART-naive subjects, LPS levels predicted the total
specific IgG antibody response to pneumococcal vaccine
(Table 2). The adjusted estimate for LPS was 22.62 (95% CI:
24.06–21.17), which suggests LPS is an inverse, independent
predictor of antibody response in untreated HIV-patients. No
associations between vaccine responses and sCD14, anti-Gal
immunoglobulins, or pro-inflammatory markers were found
among HAART-naive subjects. In HAART-treated individuals,
Figure 2. PBMC responsiveness to HIV RNA and LPS. (A) TNF-a stimulation index (SI) in HAART-naive and HAART-treated HIV-infected PBMCs
stimulated with LPS (p=0.03). (B) IFN-a SI in HAART-naive and HAART-treated HIV-infected PBMCs stimulated with LPS (p=0.002). (C) IFN-c SI in
HAART-naive and HAART-treated HIV-infected PBMCs stimulated with LPS (p=0.003). (D) TNF-a SI (log10) vs. HIV RNA (log10) in LPS-stimulated
HAART-naive HIV-infected PBMCs, p,0.001. (E) Level of TNF-a in healthy PBMCs left untreated or primed with 0.1 mg/mL of ssRNA40 or ssRNA41
(control), and subsequently stimulated with LPS; unprimed vs. 0.1 mg/mL ssRNA in non-stimulated PBMCs, p,0.001, in PBMCs stimulated wth 1 ng/
mL LPS, p,0.001, PBMCs stimulated with 10 ng/mL LPS, p,0.001, and PBMCs stimulated with 100 ng/mL LPS, p,0.001. Experiment was performed
on PBMCs from four independent donors. Results depicted from one representative stimulation experiment, performed in triplicate.
doi:10.1371/journal.pone.0021275.g002
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while the adjusted estimate for IL-6 indicated no association with the
vaccine response (p=0.13). No other markers predicted antibody
response in HAART-treated patients.
Discussion
In this study, we evaluated the independent impact of microbial
translocation and pro-inflammation on innate and adaptive
immune responses. Interestingly, we found an inverse relation
between baseline serum LPS and subsequent adaptive immune
response in HAART-naive individuals. This association was not
observed among HAART-treated subjects. We also found the
release of pro-inflammatory cytokines after LPS stimulation was
increased in PBMCs from viremic HAART-naive subjects
compared to HAART-treated subjects, as well as in PBMCs from
healthy controls pre-treated with HIV-1-derived RNA, and similar
findings have been demonstrated in previous studies [20,27].
Further, the TNF-a response depended more on increasing HIV
RNA levels than on changes in LPS level. Thus, LPS may act in
synergy with HIV RNA and cause a disruption of adaptive
immune functions by inappropriate immune diversion.
Anti-Gal immunoglobulins are potential novel markers for
microbial translocation and HIV infection. Specific anti-Gal
antibodies make up approximately 1% of circulating IgG
antibodies [8,28]. We did not however observe any differences
in concentrations of anti-Gal antibodies between HIV-infected
individuals and controls. One possible caveat is that we did not
have information about the subjects’ ABO-group statuses, which
may have influenced the results [29], since it is possible with
interference due to cross-activity between B antigen and a-Gal
antigen. The lack of differences may also have resulted from
compromised adaptive immune responses due to HIV-infection
where additional antibodies cannot be produced, although the
load of a-galactosyl epitopes may be increased. The mechanisms
are not fully established and further investigations are needed
before anti-Gal immunoglobulins can be used as markers of
microbial translocation in HIV-infected subjects. Thus, serum
concentration production of anti-Gal immunoglobulins seems
unaffected by HIV-infection, but further studies must be
conducted before it is certain how anti-Gal immunoglobulins act
in HIV-infected individuals.
We did not retrieve any association between endoCAb and LPS
or endoCAb and sCD14, while another study found an inverse
correlation to LPS [16]. As sCD14 and anti-Gal immunoglobulins,
endoCAb is produced by the host and therefore in need of a
functional immune system. We found a positive correlation
between anti-Gal IgG and endoCAb, and since both are class
IgG and produced in response to foreign microbial product, it is
expectable.
This study had some limitations. A cross sectional study design
has obvious limitations due to lack of follow up. Participants in our
HAART-naive group consisted of a relatively small number
compared to other studies on microbial translocation [3,18]
though even smaller number of HAART-naive patients is seen
[30]. The strength of the results may be lower because of the small
number of patients in the HAART-naive group. Therefore it
would be relevant to enroll more HAART-naive patients in future
studies and include a follow up. We did not find any significant
difference between HAART-treated and HAART-naive individ-
uals’ level of LPS in contrast to other studies [3,19], but we
did find a trend toward difference between uninfected and
HIV-infected individuals.
No significant association was found between LPS and sCD14
in our study, which is in accordance with findings of some studies
[22] while contradicting findings from other studies [3]. The
reason for these discrepancies is not clear. However, sCD14
inhibits cell responses to LPS by diverting LPS away from
membrane-bound CD14 and by promoting LPS efflux from cell
surface and transferring it to plasma lipoproteins [31,32].
Therefore, less LPS may be present for detection in serum
samples because of the influence of larger amounts of sCD14.
LPS is the only primary marker of microbial translocation
measured in our study, since sCD14 and endoCAb are host
markers. Another primary marker, which might be relevant to
measure, could be bacterial ribosomal 16S RNA (16S rDNA),
which is found higher in HIV-infected individuals compared to
uninfected, and 16S rDNA correlates with LPS [18]. However,
there have been some discrepancies about the value of this marker
[33].
Table 2. Prediction of adaptive immune response in HAART-treated and HAART-naive HIV-infected individuals.
HAART-treated (n=76) HAART-naive (n=20)
Estimate, unadjusted Estimate, adjusted
a Estimate, unadjusted Estimate, adjusted
sCD14 20.62 (21.44–0.20) 20.41 (21.23–0.41) 20.10 (21.49–1.29) 20.26 (22.11–1.58)
LPS 0.51 (20.37–1.39) 0.75 (20.16–1.65) 20.99 (22.41–0.42) 22.62 (24.06–21.17)
EndoCAb 0.002 (20.003–0.007) 0.001 (20.004–0.006) 20.003 (20.01–0.006) 20.003 (20.01–0.007)
Anti-Gal IgM 0.16 (20.20–0.52) 0.08 (20.28–0.43) 0.20 (20.19–0.59) 0.46 (20.13–1.04)
Anti-Gal IgG 20.04 (20.29–0.21) 20.03 (20.28–0.21) 20.09 (20.48–0.29) 20.07 (20.67–0.52)
sTNF-rII 0.05 (20.79–0.89) 0.35 (20.48–1.19) 20.21 (22.01–1.58) 0.05 (22.33–2.42)
IL-1Ra 0.27 (20.22–0.77) 0.20 (20.29–0.69) 0.11 (21.42–1.64) 1.04 (21.04–3.12)
IL-6 20.35 (20.70–20.01) 20.28 (20.65–0.08) 20.33 (20.87–0.22) 20.18 (20.88–0.51)
hs-CRP 20.15 (20.45–0.14) 20.05 (20.35–0.24) 20.23 (20.84–0.38) 20.05 (20.93–0.83)
IL-10 0.19 (20.26–0.63) 0.20 (20.25–0.65) 0.14 (20.48–0.75) 0.32 (20.54–1.17)
The predictive estimate of soluble markers for microbial translocation and pro-inflammation on adaptive immune response after pneumococcal vaccine in HAART-
treated and HAART-naive HIV-infected individuals demonstrated by estimate and 95% confidence interval. LPS was found as an independent predictor after adjustment
and mulitiple comparison.
aAdjustment for current smoking status, pre-vaccinated CD4+ cell count, age, HIV RNA (log10), and 6TLR9-agonist in the pneumococcal vaccine.
doi:10.1371/journal.pone.0021275.t002
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Protocol samples were collected at three immunizations and at
follow-up [23], which allowed us to study the association of pre-
vaccination markers with adaptive immune responses prospec-
tively. The cytokine response to LPS stimulation in PBMCs from
HIV-infected subjects suggested a connection between in vivo
HIV plasma RNA levels and the ex vivo magnitude of pro-
inflammatory response. In addition, PBMCs from healthy controls
primed with HIV-1-derived RNA displayed a TNF-a response
that was independent of increases in LPS concentration. Thus,
TNF-a production appears to be amplified by the presence of HIV
RNA and LPS and is consistent with findings of recent studies
[20,27], which likewise demonstrated that LPS stimulation of
HIV-infected PBMCs revealed a significant increase in TNF-a
level compared to uninfected PBMCs. Collectively, our findings
suggest increasing levels of viral RNA enhance the susceptibility of
PBMCs to LPS stimulation and, thereby, further activate the
immune system.
The innate toll-like receptors (TLRs) recognize pathogens and,
upon activation, induce and direct immune responses. HIV single-
stranded RNA, a TLR7- and TLR8-ligand [34], triggers initiation
of viral transcription and subsequent HIV replication in dendritic
cells through TLR8 [35]. Redundancies in TLR expression and
regulation have been demonstrated with TLR4 and TLR8
[36,37]. This illustrates crosstalk between TLRs; with TLRs
sensitized to their cognate ligands resulting in further enhanced
pro-inflammatory cytokine responses, which contributes to
persistent immune activation. TLR crosstalk is present in other
conditions such as complement-TLR crosstalk, where one study
suggests that pathogens exploit this pathway besides undermining
complement and TLRs [38], and another study demonstrated that
TLR crosstalk controls B cell responses on several levels, and the
outcome of TLR crosstalk in B cells from patients with periodontal
diseases and diabetes are influenced by disease pathology [39].
Enhanced expression of TLRs and increased responsiveness to
their ligands, such as LPS in HIV-infection [37], may play an
important role in adaptive immune responses; TLRs appear to be
essential in the initiation of adaptive immune responses [40].
Normalization of TLR levels is observed after viral suppression by
HAART [37], which is consistent with our findings that lower
cytokine levels were produced by PBMCs from HAART-treated
subjects compared with HAART-naive patients. Concurrently, in
HAART-treated individuals, adaptive immune responses were not
predicted by LPS, thereby indicating a positive effect of treatment
on both innate and adaptive immunity.
Pneumonia is more common in HIV-infected individuals with a
6-fold higher incidence than in HIV-uninfected individuals [41]
leading to excess morbidity and mortality [41,42]. Immune
responses to immunization in HIV-populations appear superior
in subjects on HAART with suppressed HIV RNA compared to
viremic HAART-naive HIV-infected subjects [43,44]. In accor-
dance with our results, the effect of immunization appear greater
in HIV-infected subjects on HAART.
It is important to further investigate pneumococcal vaccination
effectiveness in HIV-infected subjects in relation to microbial
translocation and innate immune function. If our findings translate
in to clinical effectiveness, then increased LPS levels at the time of
immunization would independently predict vaccine failure in
HAART naive individuals.
There is a great deal of uncertainty regarding the relationship
between HIV disease progression and microbial translocation and
subsequent inflammatory immune responses [22]. Though
antibody response is not a clinical endpoint, a recent study
showed vaccination responses following hepatitis B immunization
predicted HIV disease progression (Landrum et al., at Conference
on retroviruses and opportunistic infections, 2010:625). In need of
clinical endpoints, adaptive immune responses may thus be viewed
as a surrogate marker of HIV disease progression. However, it
should be noted that due to the above-mentioned limitations and
to the study design, our findings could not establish a causal link
between microbial translocation and immune activation and HIV
disease progression.
In conclusion, we found LPS to be an independent predictor of
adaptive immune response in untreated HIV-infected individuals.
Our results suggest HIV RNA and LPS act in synergy and that
their concerted action brings about increased cytokine respon-
siveness through innate immune recognition pathways. By
reducing viremia, HAART treatment increases the tolerance to
LPS, which in turn reduces further immune activation. Hence,
earlier initiation of HAART may offset the immune disruption
caused by microbial translocation and should be investigated in
future studies.
Supporting Information
Figure S1 PBMC responsiveness to HIV RNA and LPS.
(A) Level of TNF-a in healthy PBMCs left untreated or primed
with 0.01 mg/mL of ssRNA40 or ssRNA41 (control), and
subsequently stimulated with LPS; unprimed vs. 0.01 mg/mL
ssRNA in unstimulated PBMCs (p=0.13), in PBMCs stimulated
wth 1 ng/mL LPS (p=0.32), PBMCs stimulated with 10 ng/mL
LPS (p=0.14), and PBMCs stimulated with 100 ng/mL LPS
(p=0.32). (B) Level of TNF-a in healthy PBMCs left untreated or
primed with 1.0 mg/mL of ssRNA40 or ssRNA41 (control), and
subsequently stimulated with LPS; unprimed vs. 1.0 mg/mL
ssRNA in unstimulated PBMCs (p,0.0001), in PBMCs stimulated
wth 1 ng/mL LPS (p,0.0001), PBMCs stimulated with 10 ng/
mL LPS (p,0.001), and PBMCs stimulated with 100 ng/mL LPS
(p,0.002). Both experiments were performed on PBMCs from
four independent donors. Results depicted from one representative
stimulation experiment, performed in triplicate.
(TIF)
Text S1 Flowchart from main trial.
(PDF)
Text S2 Pneumococcal CPG7909 protocol from main trial.
(DOC)
Acknowledgments
The authors thank the participants in the pneumococcal vaccine study.
They also thank Kirsten Stadel Petersen and Søren Riss Paludan
(Department of Medical Microbiology and Immunology, Aarhus Univer-
sity, Denmark), for luminex measurements, and the blood bank at Aarhus
University Hospital, Skejby, Denmark, for collecting blood samples from
HIV-uninfected controls.
Author Contributions
Conceived and designed the experiments: ARB OSS MT LT RO JM
JMBJ LØ. Performed the experiments: ARB JM RO JMBJ. Analyzed the
data: ARB OSS RO . Contributed reagents/materials/analysis tools: JMBJ
HS. Wrote the paper: ARB . Designed software used in analysis: HS.
Impact of LPS on Adaptive Immunity
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e21275References
1. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, et al. (2004) CD4+
T cell depletion during all stages of HIV disease occurs predominantly in the
gastrointestinal tract. J Exp Med 200: 749–759.
2. Dandekar S (2007) Pathogenesis of HIV in the gastrointestinal tract. Curr HIV/
AIDS Rep 4: 10–15.
3. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al. (2006)
Microbial translocation is a cause of systemic immune activation in chronic HIV
infection. Nat Med 12: 1365–1371.
4. Epple HJ, Schneider T, Troeger H, Kunkel D, Allers K, et al. (2009)
Impairment of the intestinal barrier is evident in untreated but absent in
suppressively treated HIV-infected patients. Gut 58: 220–227.
5. Nazli A, Chan O, Dobson-Belaire WN, Ouellet M, Tremblay MJ, et al. (2010)
Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing
microbial translocation. PLoS Pathog 6: e1000852.
6. Lee PI, Ciccone EJ, Read SW, Asher A, Pitts R, et al. (2009) Evidence for
translocation of microbial products in patients with idiopathic CD4 lymphocy-
topenia. J Infect Dis 199: 1664–1670.
7. D’Alessandro M, Mariani P, Lomanto D, Bachetoni A, Speranza V (2002)
Alterations in serum anti-alpha-galactosyl antibodies in patients with Crohn’s
disease and ulcerative colitis. Clin Immunol 103: 63–68.
8. Galili U (1993) Evolution and pathophysiology of the human natural anti-alpha-
galactosyl IgG (anti-Gal) antibody. Springer Semin Immunopathol 15: 155–171.
9. Galili U, Mandrell RE, Hamadeh RM, Shohet SB, Griffiss JM (1988)
Interaction between human natural anti-alpha-galactosyl immunoglobulin G
and bacteria of the human flora. Infect Immun 56: 1730–1737.
10. Macher BA, Galili U (2008) The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal)
epitope: a carbohydrate of unique evolution and clinical relevance. Biochim
Biophys Acta 1780: 75–88.
11. Maes M, Kubera M, Leunis JC (2008) The gut-brain barrier in major
depression: intestinal mucosal dysfunction with an increased translocation of
LPS from gram negative enterobacteria (leaky gut) plays a role in the
inflammatory pathophysiology of depression. Neuro Endocrinol Lett 29:
117–124.
12. Choudhry MA, Rana SN, Kavanaugh MJ, Kovacs EJ, Gamelli RL, et al. (2004)
Impaired intestinal immunity and barrier function: a cause for enhanced
bacterial translocation in alcohol intoxication and burn injury. Alcohol 33:
199–208.
13. Yu P, Martin CM (2000) Increased gut permeability and bacterial translocation
in Pseudomonas pneumonia-induced sepsis. Crit Care Med 28: 2573–2577.
14. Besselink MG, van Santvoort HC, Renooij W, de Smet MB, Boermeester MA,
et al. (2009) Intestinal barrier dysfunction in a randomized trial of a specific
probiotic composition in acute pancreatitis. Ann Surg 250: 712–719.
15. Bode C, Bode JC (2003) Effect of alcohol consumption on the gut. Best Pract Res
Clin Gastroenterol 17: 575–592.
16. Ancuta P, Kamat A, Kunstman KJ, Kim EY, Autissier P, et al. (2008) Microbial
translocation is associated with increased monocyte activation and dementia in
AIDS patients. PLoS One 3: e2516.
17. Marchetti G, Bellistri GM, Borghi E, Tincati C, Ferramosca S, et al. (2008)
Microbial translocation is associated with sustained failure in CD4+ T-cell
reconstitution in HIV-infected patients on long-term highly active antiretroviral
therapy. AIDS 22: 2035–2038.
18. Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, et al. (2009) Plasma levels
of bacterial DNA correlate with immune activation and the magnitude of
immune restoration in persons with antiretroviral-treated HIV infection. J Infect
Dis 199: 1177–1185.
19. Rajasuriar R, Booth D, Solomon A, Chua K, Spelman T, et al. (2010) Biological
Determinants of Immune Reconstitution in HIV-Infected Patients Receiving
Antiretroviral Therapy: The Role of Interleukin 7 and Interleukin 7 Receptor
alpha and Microbial Translocation. J Infect Dis 202: 1254–1264.
20. Lester RT, Yao XD, Ball TB, McKinnon LR, Omange WR, et al. (2009) HIV-1
RNA dysregulates the natural TLR response to subclinical endotoxemia in
Kenyan female sex-workers. PLoS One 4: e5644.
21. Nowroozalizadeh S, Mansson F, da Silva Z, Repits J, Dabo B, et al. (2010)
Microbial translocation correlates with the severity of both HIV-1 and HIV-2
infections. J Infect Dis 201: 1150–1154.
22. Redd AD, Dabitao D, Bream JH, Charvat B, Laeyendecker O, et al. (2009)
Microbial translocation, the innate cytokine response, and HIV-1 disease
progression in Africa. Proc Natl Acad Sci U S A 106: 6718–6723.
23. Søgaard OS, Lohse N, Harboe ZB, Offersen R, Bukh AR, et al. (2010)
Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-
infected adults with a toll-like receptor 9 agonist adjuvant: a randomized,
controlled trial. Clin Infect Dis 51: 42–50.
24. Søgaard OS, Schonheyder HC, Bukh AR, Harboe ZB, Rasmussen TA, et al.
(2010) Pneumococcal conjugate vaccination in persons with HIV: the effect of
highly active antiretroviral therapy. AIDS 24: 1315–1322.
25. Konradsen HB, Sorensen UB, Henrichsen J (1993) A modified enzyme-linked
immunosorbent assay for measuring type-specific anti-pneumococcal capsular
polysaccharide antibodies. J Immunol Methods 164: 13–20.
26. Skovsted IC, Kerrn MB, Sonne-Hansen J, Sauer LE, Nielsen AK, et al. (2007)
Purification and structure characterization of the active component in the
pneumococcal 22F polysaccharide capsule used for adsorption in pneumococcal
enzyme-linked immunosorbent assays. Vaccine 25: 6490–6500.
27. Mureith MW, Chang JJ, Lifson JD, Ndung’u T, Altfeld M (2010) Exposure to
HIV-1-encoded Toll-like receptor 8 ligands enhances monocyte response to
microbial encoded Toll-like receptor 2/4 ligands. AIDS 24: 1841–1848.
28. Saethre M, Solvik UO, Haraldsen G, Fiane AE, Boretti E, et al. (2002) Human
serum-induced porcine endothelial cell E-selectin expression is associated with
IgG3 and IgM anti-Gal antibodies. Xenotransplantation 9: 350–358.
29. Galili U, Buehler J, Shohet SB, Macher BA (1987) The human natural anti-Gal
IgG. III. The subtlety of immune tolerance in man as demonstrated by
crossreactivity between natural anti-Gal and anti-B antibodies. J Exp Med 165:
693–704.
30. Papasavvas E, Pistilli M, Reynolds G, Bucki R, Azzoni L, et al. (2009) Delayed
loss of control of plasma lipopolysaccharide levels after therapy interruption in
chronically HIV-1-infected patients. AIDS 23: 369–375.
31. Kitchens RL, Thompson PA, Viriyakosol S, O’Keefe GE, Munford RS (2001)
Plasma CD14 decreases monocyte responses to LPS by transferring cell-bound
LPS to plasma lipoproteins. J Clin Invest 108: 485–493.
32. Kitchens RL, Thompson PA (2005) Modulatory effects of sCD14 and LBP on
LPS-host cell interactions. J Endotoxin Res 11: 225–229.
33. Ferri E, Novati S, Casiraghi M, Sambri V, Genco F, et al. (2010) Plasma levels of
bacterial DNA in HIV infection: the limits of quantitative polymerase chain
reaction. J Infect Dis 202: 176-177; author reply 178.
34. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, et al. (2004)
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and
8. Science 303: 1526–1529.
35. Gringhuis SI, van der Vlist M, van den Berg LM, den Dunnen J, Litjens M, et
al. (2010) HIV-1 exploits innate signaling by TLR8 and DC-SIGN for
productive infection of dendritic cells. Nat Immunol 11: 419–426.
36. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, et al. (1998) Defective
LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene.
Science 282: 2085–2088.
37. Lester RT, Yao XD, Ball TB, McKinnon LR, Kaul R, et al. (2008) Toll-like
receptor expression and responsiveness are increased in viraemic HIV-1
infection. AIDS 22: 685–694.
38. Wang M, Krauss JL, Domon H, Hosur KB, Liang S, et al. (2010) Microbial
hijacking of complement-toll-like receptor crosstalk. Sci Signal 3: ra11.
39. Jagannathan M, Hasturk H, Liang Y, Shin H, Hetzel JT, et al. (2009) TLR
cross-talk specifically regulates cytokine production by B cells from chronic
inflammatory disease patients. J Immunol 183: 7461–7470.
40. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, et al. (2001) Toll-like
receptors control activation of adaptive immune responses. Nat Immunol 2:
947–950.
41. Søgaard OS, Lohse N, Gerstoft J, Kronborg G, Østergaard L, et al. (2008)
Hospitalization for pneumonia among individuals with and without HIV
infection, 1995-2007: a Danish population-based, nationwide cohort study. Clin
Infect Dis 47: 1345–1353.
42. Nuorti JP, Butler JC, Gelling L, Kool JL, Reingold AL, et al. (2000)
Epidemiologic relation between HIV and invasive pneumococcal disease in
San Francisco County, California. Ann Intern Med 132: 182–190.
43. Gonzalez R, Castro P, Garcia F, Plana M, Bayas JM, et al. (2010) Effects of
highly active antiretroviral therapy on vaccine-induced humoral immunity in
HIV-infected adults. HIV Med 11: 535–539.
44. Subramaniam KS, Segal R, Lyles RH, Rodriguez-Barradas MC, Pirofski LA
(2003) Qualitative change in antibody responses of human immunodeficiency
virus-infected individuals to pneumococcal capsular polysaccharide vaccination
associated with highly active antiretroviral therapy. J Infect Dis 187: 758–768.
Impact of LPS on Adaptive Immunity
PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e21275